MannKind Corporation (United States)

Recent papers from MannKind Corporation (United States)

1. Microbes as Primary Architects of Planetary Habitability2026
2. Inhaled Insulin Dosing in a Randomized Trial in Adults With Type 1 DiabetesAACE Endocrinology and Diabetes · 2026
3. Replacing or Supplementing Automated Insulin Delivery With Inhaled Insulin: A 90-Day Randomized Controlled TrialJournal of Diabetes Science and Technology · 2025
4. Replacing or Supplementing Automated Insulin Delivery With Inhaled Insulin: A 90-Day Randomized Controlled TrialJournal of Diabetes Science and Technology · 2025
5. Safety and Efficacy of Inhaled Technosphere® Insulin in the Postprandial Period With Modified Initial Dose ConversionDiabetes Therapy · 2025
6. Tyvaso DPI: Drug-device characteristics and patient clinical considerationsPulmonary Pharmacology & Therapeutics · 2023
7. Time–Action Profile of Technosphere Insulin in Children with Type 1 DiabetesDiabetes Therapy · 2023
8. Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria InfectionAntimicrobial Agents and Chemotherapy · 2023
9. Building the 2022 Diabetes Technology Practice Competencies Using Modified Delphi MethodologyThe Science of Diabetes Self-Management and Care · 2022
10. Reduction in Postprandial Peak Glucose With Increased Technosphere Insulin DosageJournal of Diabetes Science and Technology · 2022
11. Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes MellitusClinical Pharmacokinetics · 2021
12. Results of a 24-Week Trial of Technosphere Insulin Versus Insulin Aspart in Type 2 DiabetesEndocrine Practice · 2020
13. Understanding inhaled Technosphere Insulin: Results of an early randomized trial in type 1 diabetes mellitusJournal of Diabetes · 2020
14. Comprehensive Pulmonary Safety Review of Inhaled Technosphere® Insulin in Patients with Diabetes MellitusClinical Drug Investigation · 2020
15. Hypoglycaemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitusDiabetic Medicine · 2019
16. Autophagy and the unfolded protein response promote profibrotic effects of TGF-β₁ in human lung fibroblastsAJP Lung Cellular and Molecular Physiology · 2017
17. Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled InsulinJournal of Diabetes Science and Technology · 2016
18. Endoplasmic reticulum stress-mediated induction of SESTRIN 2 potentiates cell survivalOncotarget · 2016
19. Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes AgentsDiabetes Care · 2015
20. Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week TrialDiabetes Care · 2015